Crescent Biopharma
CBIO
75 hedge funds and large institutions have $180M invested in Crescent Biopharma in 2019 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 25 closing their positions.
185% more call options, than puts
Call options by funds: $94K | Put options by funds: $33K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
0% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 19
0.08% less ownership
Funds ownership: 1.04% → 0.96% (-0.08%)
4% less funds holding
Funds holding: 78 → 75 (-3)
12% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 25
66% less capital invested
Capital invested by funds: $535M → $180M (-$356M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$47.3M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$22.5M |
| 3 |
Millennium Management
New York
|
+$1.27M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$1.06M |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$859K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$36.3M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$26.8M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$20.5M |
| 4 |
Jennison Associates
New York
|
-$16.9M |
| 5 |
Janus Henderson Group
London,
|
-$13.1M |
CBIO Hedge Fund Activity: Q3 2019 in Review
75 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Crescent Biopharma (CBIO) for Q3 2019, worth a combined $180M — down 66% from $535M a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of CBIO and 22 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 19 added.
The largest buyer was BVF Inc, opening a new position worth an estimated $47.3M. The largest seller was T. Rowe Price Associates, exiting entirely with an estimated $36.3M sold.
- 75 institutional investors held Crescent Biopharma (CBIO) as of Q3 2019, down from 78 in Q2 2019.
- Funds reported $180M of Crescent Biopharma stock for Q3 2019, down 66% quarter-over-quarter.
- 22 funds opened new Crescent Biopharma positions in Q3 2019 and 25 closed out, a net change of -3 holders.
- The largest Crescent Biopharma buyer in Q3 2019 was BVF Inc, an estimated $47.3M added.
- The largest Crescent Biopharma seller in Q3 2019 was T. Rowe Price Associates, an estimated $36.3M sold.
Based on aggregated 13F filings for Q3 2019.